financetom
Business
financetom
/
Business
/
Danaher Expects Increase in Q4 Revenue YOY vs Street View for Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Danaher Expects Increase in Q4 Revenue YOY vs Street View for Decline
Jan 13, 2025 2:14 PM

04:57 PM EST, 01/13/2025 (MT Newswires) -- Danaher ( DHR ) late Monday said revenue during its recently completed Q4 will likely increase in the low-single digit percentage range, compared with $6.41 billion in the year-ago period.

Analysts polled by FactSet, on average, are expecting a year-over-year decline in revenue for the three months ended Dec. 31 to around $6.38 billion.

The company also said it sees flat Q4 non-GAAP core revenue compared with the final three months of 2023, although that still would be an improvement from its previous guidance expecting a low-single digit percentage decline.

Danaher ( DHR ) released its preliminary revenue ahead of a presentation on Tuesday by Chief Executive Officer Rainer M. Blair at the JPMorgan Healthcare Conference. The company is scheduled to release its Q4 financial results on Jan. 29.

Danaher ( DHR ) shares were fractionally lower in the extended session.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3 - Alpha Group International plc
Form 8.3 - Alpha Group International plc
Sep 29, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Sep 29, 2025
Genmab A/S ( GMAB ) on Monday agreed to acquire Merus N.V ( MRUS ). with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion. The transaction is anticipated to close by early in the first quarter of 2026. The proposed acquisition of...
Form 8.3 - Dowlais Group plc
Form 8.3 - Dowlais Group plc
Sep 29, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Form 8.3 - Spirent Communications plc
Form 8.3 - Spirent Communications plc
Sep 29, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved